Show simple item record

dc.contributor.authorAtaollah Hiradfar, A
dc.contributor.authorRezamand, A
dc.contributor.authorPourghasem, M
dc.contributor.authorKarkon Shayan, S
dc.contributor.authorGhamari, B
dc.contributor.authorKarkon Shayan, F
dc.date.accessioned2018-08-26T09:33:25Z
dc.date.available2018-08-26T09:33:25Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/57548
dc.description.abstractBackground: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemotherapy-induced anemia is crucial. This study was aimed to evaluate the efficacy of recombinant human erythropoietin in reducing the need for blood transfusion in children with solid tumors receiving chemotherapy. Methods: In a clinical trial, 57 children referred to the pediatric centre of Tabriz University of Medical Sciences with a diagnosis of solid tumor were randomly assigned into two groups. The intervention group (n=29) received recombinant human erythropoietin (rHuEPO) at a dose of 450 IU/kg subcutaneously once a week for 12 weeks, and the control group (n=28) received no intervention in this regard. Hemoglobin levels were analysed at the beginning and end of the study. The need for blood transfusion was also assessed in the patients. Results: The mean Hb at the beginning of the study was 8.85آ±1.01 and 8.98آ±0.11 g in the intervention and control groups, respectively. The mean Hb at the end of the study was 9.78آ±0.32 g/dl in the intervention group and 7.79آ±0.24 g/dl in the control group. Hb level was significantly higher in the intervention group at the end of the 12 weeks of treatment with rHuEPO than in the control group (P=0.001). Conclusion: Based on the results of this study, rHuEPO administration seems to be beneficial in the prevention and treatment of chemotherapy-induced anemia in children with solid tumors and reduces the amount of blood transfusion in these patients. آ© 2018, Iranian Pediatric Hematology and Oncology Society. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofIranian Journal of Blood and Cancer
dc.subjectcisplatin
dc.subjectdoxorubicin
dc.subjectferritin
dc.subjecthemoglobin
dc.subjectrecombinant erythropoietin
dc.subjectvincristine
dc.subjectArticle
dc.subjectblood transfusion
dc.subjectbone pain
dc.subjectcancer chemotherapy
dc.subjectchemotherapy induced anemia
dc.subjectchild
dc.subjectcontrolled study
dc.subjectdisease exacerbation
dc.subjectependymoma
dc.subjectEwing sarcoma
dc.subjectfemale
dc.subjectfever
dc.subjectflu like syndrome
dc.subjectflushing
dc.subjectglioblastoma
dc.subjecthemoglobin blood level
dc.subjecthepatoblastoma
dc.subjecthuman
dc.subjecthypertension
dc.subjectlength of stay
dc.subjectlymphoma
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectneuroblastoma
dc.subjectnonhodgkin lymphoma
dc.subjectpreschool child
dc.subjectquality of life
dc.subjectrandomized controlled trial
dc.subjectsolid malignant neoplasm
dc.subjectsynovial sarcoma
dc.subjecttumor growth
dc.subjectvomiting
dc.titleRecombinant human erythropoietin in children with solid tumors and chemotherapy-induced anemia
dc.typeArticle
dc.citation.volume10
dc.citation.issue1
dc.citation.spage9
dc.citation.epage15
dc.citation.indexScopus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record